Krejsa, Cecile M <br/><br/>
Interleukin-21 enhances rituximab activity in a cynomolgus monkey model of B cell depletion and in mouse B cell lymphoma models.  [electronic resource] 

 -  PloS one  2013 
 - e67256 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1932-6203 
<br/><br/><label>Standard No.: </label>10.1371/journal.pone.0067256  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Antibodies, Monoclonal, Murine-Derived--pharmacology<br/>Antibody-Dependent Cell Cytotoxicity--drug effects<br/>Antineoplastic Agents--pharmacology<br/>B-Lymphocytes--cytology<br/>Cell Line, Tumor<br/>Disease Models, Animal<br/>Drug Synergism<br/>Female<br/>Humans<br/>Immunity, Innate--drug effects<br/>Interleukins--pharmacology<br/>Lymphoma, B-Cell--drug therapy<br/>Macaca fascicularis<br/>Male<br/>Mice<br/>Rituximab<br/>Survival Analysis<br/>Interleukin-21